Cone Rod Dystrophy Companies

Beacon Therapeutics Secures $120 Million Funding for Gene Therapy Development: Beacon Therapeutics, a UK-based company, received $120 million in funding to develop gene therapies for retinal diseases, including CRD. This investment will support the clinical development of their lead candidate, BEACON-RPE, which targets the RPE65 gene mutation responsible for a form of CRD.

MeiraGTx Initiates Phase 1/2 Trial for Retinal Gene Therapy: MeiraGTx, a US-based company, began a Phase 1/2 clinical trial evaluating their MGT009 gene therapy for the treatment of Leber's congenital amaurosis (LCA), a form of CRD. This trial represents a significant step forward in developing gene therapy for CRD patients.

Spark Therapeutics Announces Positive Phase 3 Data for Gene Therapy: Spark Therapeutics, a US-based company, reported positive results from their Phase 3 trial of SPARC64, a gene therapy for LCA. These results suggest that SPARC64 could potentially offer a one-time treatment option for LCA patients, including those with CRD.

List of Cone-Rod Dystrophy Key Companies in the Market

• GlaxoSmithKline Plc. (U.S.)


• Johnson & Johnson (U.S.)


• Sanofi (Switzerland)


• Pfizer Inc. (U.S.)


• Novartis AG (Switzerland)


• Abbott Laboratories (U.S.)


• Sunovion Pharmaceuticals (U.S.)


• Cephalon (U.S.)


• DSM (India)


• Amway (U.S.)


• Vitamin Shoppe (U.S.)


• Intas Pharmaceutials Limited (India)


• Sun Pharmaceuticals Ltd. (India)


• Emcure Pharmaceuticals Limited (India)


• Nutrilite (U.S.)


• NutraScience Labs (U.S.)